Celgene Corporation (CELG) : Peddock Capital Advisors scooped up 61 additional shares in Celgene Corporation during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 14, 2016. The investment management firm now holds a total of 12,451 shares of Celgene Corporation which is valued at $1,226,424.Celgene Corporation makes up approximately 0.81% of Peddock Capital Advisors’s portfolio.
Other Hedge Funds, Including , Webster Bank N. A. reduced its stake in CELG by selling 10 shares or 0.23% in the most recent quarter. The Hedge Fund company now holds 4,428 shares of CELG which is valued at $436,158. Celgene Corporation makes up approx 0.06% of Webster Bank N. A.’s portfolio.Headinvest boosted its stake in CELG in the latest quarter, The investment management firm added 1,700 additional shares and now holds a total of 23,100 shares of Celgene Corporation which is valued at $2,408,637. Celgene Corporation makes up approx 0.86% of Headinvest’s portfolio.Hudson Valley Investment Advisors Inc Adv boosted its stake in CELG in the latest quarter, The investment management firm added 2,586 additional shares and now holds a total of 14,508 shares of Celgene Corporation which is valued at $1,512,749. Celgene Corporation makes up approx 0.47% of Hudson Valley Investment Advisors Inc Adv’s portfolio. Simplex Trading sold out all of its stake in CELG during the most recent quarter. The investment firm sold 116,614 shares of CELG which is valued $12,136,019.Harbour Capital Advisors reduced its stake in CELG by selling 80 shares or 0.74% in the most recent quarter. The Hedge Fund company now holds 10,799 shares of CELG which is valued at $1,137,027. Celgene Corporation makes up approx 0.61% of Harbour Capital Advisors’s portfolio.
Celgene Corporation closed down -2.13 points or -2.12% at $98.5 with 43,17,515 shares getting traded on Friday. Post opening the session at $101.25, the shares hit an intraday low of $98.48 and an intraday high of $101.389 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, Celgene Corporation reported $1.44 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $1.39. The company had revenue of $2754.00 million for the quarter, compared to analysts expectations of $2709.02 million. The company’s revenue was up 20.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.23 EPS.
Celgene Corporation (Celgene) together with its subsidiaries is an integrated biopharmaceutical company engaged primarily in the discovery development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Companys primary commercial stage products include REVLIMID (lenalidomide) ABRAXANE POMALYST/IMNOVID VIDAZA azacitidine for injection (generic version of VIDAZA) THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States) OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies targeting areas including intracellular signaling pathways protein homeostasis and epigenetics in cancer and immune cells immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.